Abstract
This note highlights our understanding and thinking about the feasibility of l-asparaginase as therapeutics for multiple diseases. l-asparaginase enzyme (l-asparagine amidohydrolase, EC 3.5.1.1) is prominently known for its chemotherapeutic application. It is primarily used in the treatment of acute lymphoblastic leukemia in children. It is also used in the treatment of other forms of cancer Hodgkin disease, lymphosarcoma, acute myelomonocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma (Lopes et al. Crit Rev Biotechnol 23:1–18, 2015). It deaminates l-asparagine present in the plasma pool causing the demise of tumor cell due to nutritional starvation. The anti-tumorigenic property of this enzyme has been exploited for over four decades and evidenced as a boon for the cancer patients. Presently, the medical application of l-asparaginase is limited only in curing various forms of cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Baruch M, Belotserkovsky I, Hertzog BB et al (2014a) An extracellular bacterial pathogen modulates host metabolism to regulate its own sensing and proliferation. Cell 156:97–108. https://doi.org/10.1016/j.cell.2013.12.007
Baruch M, Hertzog BB, Ravins M et al (2014b) Induction of endoplasmic reticulum stress and unfolded protein response constitutes a pathogenic strategy of group A streptococcus. Front Cell Infect Microbiol 4:1–5. https://doi.org/10.3389/fcimb.2014.00105
Eckhardt M, Barth H, Blo D, Aktories K (2000) Binding of clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. J Biol Chem 275:2328–2334
Gesbert G, Ramond E, Rigard M et al (2014) Asparagine assimilation is critical for intracellular replication and dissemination of Francisella. Cell Microbiol 16:434–449. https://doi.org/10.1111/cmi.12227
Gieldanowski J (1976) Studies on the immunosuppressive and anti-inflammatory action of L-asparaginase. Arch Immunol Ther Exp (Warsz) 24:243–247
Lopes AM, Oliveira-nascimento L, Ribeiro A et al (2015) Therapeutic l-asparaginase: upstream, downstream and beyond. Crit Rev Biotechnol 23:1–18. https://doi.org/10.3109/07388551.2015.1120705
Reiff A, Zastrow M, Sun BC et al (2001) Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol 19:639–646
Saba CF, Hafeman SD, Vail DM, Thamm DH (2009) Combination chemotherapy with continuous l-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. J Vet Intern Med 23:1058–1063
Saito A, Ochiai K, Kondo S et al (2011) Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2. J Biol Chem 286:4809–4818. https://doi.org/10.1074/jbc.M110.152900
Vimal A, Kumar A (2017) In vitro screening and in silico validation revealed key microbes for higher production of significant therapeutic enzyme l-asparaginase. Enzyme Microb Technol 98:9–17. https://doi.org/10.1016/j.enzmictec.2016.12.001
Acknowledgements
Authors are thankful to National Institute of Technology, Raipur (CG), India for providing facility, space and resources for this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared no conflict of interest.
Rights and permissions
About this article
Cite this article
Vimal, A., Kumar, A. l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 3 Biotech 8, 278 (2018). https://doi.org/10.1007/s13205-018-1282-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-018-1282-3